Phosphatidylinositol-3 kinases (PI3Ks) constitute a lipid kinase family integral to signalling pathways that regulate many cancer-related processes, including cell proliferation, adhesion, apoptosis, survival and motility ([@bib6]; [@bib4]). Alteration of PI3K family members, such as amplification of the phosphoinositide-3-kinase catalytic subunit alpha (*PIK3CA*) oncogene on chromosome 3q26 that encodes the p110*α* catalytic subunit of PI3K, are commonly observed in human cancers. Amplification and overexpression of *PIK3CA* results in increased production of the phosphatidylinositol-3,4,5-triphosphate second messenger, hyperactivation of the PI3K/AKT pathway, and stimulation of cellular transformation and tumour progression ([@bib19]; [@bib14]; [@bib5]; [@bib16]; [@bib17]). Somatic mutations in *PIK3CA* are also common in colon (18--32%), gastric (4--25%), endometrial (36%), liver (36%), brain (27%) and breast (18--40%) tumours ([@bib2]; [@bib3]; [@bib18]; [@bib9]; [@bib12]). Functional analyses have shown that many of these mutations activate PIK3CA enzymatic activity and stimulate downstream AKT signalling, promoting growth factor-independent growth and metastasis ([@bib18]; [@bib17]).

In breast tumours, *PIK3CA* mutations have been consistently associated with ER-positive and human epidermal growth factor receptor-2 (HER2)-positive tumour status ([@bib16]; [@bib11]; [@bib15]; [@bib20]) ([@bib16]; [@bib15]). The correlation between these mutations and breast cancer prognosis is less clear, with several studies reporting associations between *PIK3CA* mutations and lymph node metastasis and worse overall and breast cancer-specific survival ([@bib16]; [@bib11]; [@bib10]; [@bib1]), whereas other studies have reported associations with longer survival particularly among patients with ER-positive, HER2-negative tumours ([@bib15]; [@bib8]; [@bib13]).

Although the pathological and clinical significance of *PIK3CA* somatic mutations has been well studied, the contribution of inherited variation in this important oncogene to risk of breast cancer is unknown. Here we investigated the influence of germline variation in *PIK3CA* on breast cancer risk.

Materials and Methods
=====================

Mayo clinic breast cancer study
-------------------------------

The details of the Mayo Clinic Breast Cancer case--control Study (MCBCS) have been described previously ([@bib22]). Briefly, cases were comprised of Caucasian women with invasive breast cancer diagnosed within 6 months of ascertainment with no prior history of cancer. Controls were comprised of Caucasian women visiting the Mayo Clinic for general medical exams in the Department of Internal Medicine with no prior history of cancer. Participants were recruited under an Institutional Review Board approved protocol. A total of 798 cases and 843 controls were utilised for stage 1 genotyping ([Table 1](#tbl1){ref-type="table"}).

Replication studies
-------------------

The Cancer Genetic Markers of Susceptibility (CGEMS) breast cancer case--control study and 26 case--control studies from Breast Cancer Association Consortium (BCAC) contributed data to these analyses (described in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Stage 1 of the CGEMS GWAS included 1145 cases and 1142 controls of self-reported white European ancestry ([@bib21]), whereas the combined Stage 1 and 2 of CGEMS included a total of 5436 cases and 5280 controls ([Table 1](#tbl1){ref-type="table"}). The BCAC replication was comprised of 24 studies of women of primarily European descent ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}), 1702 additional samples from MCBCS and two studies (SEBCS and TBCS) of women from Southeast Asia ([Table 1](#tbl1){ref-type="table"}). Final combined analyses included 35 991 breast cancer cases and 35 153 controls of white European ancestry, as well as 2183 breast cancer cases and 1469 controls of Asian ancestry. Study participants were recruited under protocols approved by the institutional review board at each institution and all subjects provided written informed consent.

Genotyping
----------

Four haplotype-tagging single-nucleotide polymorphisms (SNPs) within *PIK3CA* (rs13320527, rs3729692, rs1607237, rs9838117) were selected (*r*^2^\>0.80 in European--American genotype data from HapMap release 21). A total of 1741 Mayo Clinic samples (798 cases, 843 controls and 100 duplicates) were genotyped on custom oligo pool assays at Illumina Corporation (San Diego, CA, USA) using the Illumina GoldenGate assay. All SNPs had genotype call rates \>95%. Concordance between duplicate samples was 100%. Genotyping of rs1607237 in CGEMS and BCAC was performed using a TaqMan allelic discrimination assay or the Sequenom platform (Sequenom, San Diego, CA, USA) via standard protocols. Genotyping concordance was verified with internal duplicates and overall data quality was ensured using independent genotyping of 96 CEU samples by each genotyping center ([@bib7]). All studies met the specified criteria for call rate (\>95%).

Pathology and tumour markers
----------------------------

The collection of pathology and tumour marker information for BCAC has been described previously ([@bib23]). Pathology data were also available for 900 CGEMS subjects. Briefly, studies provided information on histopathological subtype, grade of differentiation, tumour size, nodal involvement and stage at diagnosis of breast tumours. All studies except BBCS, GC-HBOC and HMBCS provided data on ER and progesterone receptor (PR) status of tumours, and 12 studies provided data on HER2 ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). ER/PR status was most commonly defined using data from medical records. Oestrogen receptor and PR negative status was defined as \<10% of the tumour cells stained. Human epidermal growth factor receptor-2-negative status was typically defined as a score of 0 or 1+ on a HER2 immunohistochemistry (IHC) scale of 0--3+.

Statistical methods
-------------------

Evidence of departure from Hardy--Weinberg equilibrium (HWE) was assessed in controls using a goodness of fit test and none was observed (HWE *P*⩾0.001). Single-nucleotide polymorphism associations were tested using unconditional logistic regression adjusting for age and state of residence in a log-additive model. We also calculated odds ratios (ORs) and 95% confidence intervals (CIs) separately for heterozygotes and rare homozygotes. The association between rs1607237 and breast cancer risk in stage 1 of the CGEMS GWAS was evaluated as previously described ([@bib21]). Associations with breast cancer risk in the BCAC studies and the combined BCAC, MCBCS and CGEMS studies were evaluated using unconditional logistic regression adjusting for study center. A likelihood ratio test of heterogeneity by age groups was not significant (*P*=0.10), and further adjustment for age did not change the results. Analyses of pathology-specific subsets of cases were conducted using polytomous regression with controls as the reference outcome, adjusting for study site.

Results
=======

Of four *PIK3CA* haplotype-tagging SNPs, rs1607237 was significantly associated with risk of breast cancer in MCBCS (OR=0.85, 95% CI 0.73--0.98, *P*=0.023; [Table 2](#tbl2){ref-type="table"}, [Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). Next we evaluated associations between rs1607237 and breast cancer risk in 1145 cases and 1142 controls genotyped in stage 1 of the CGEMS breast cancer GWAS ([@bib21]). Rs1607237 was significantly associated with breast cancer risk (heterozygous OR=1.12, homozygous OR=0.79, score *P*=0.017). To provide a more stable estimate of risk in this population, 8429 additional CGEMS subjects were genotyped for rs1607237. In all 5436 cases and 5280 controls from stage 1 and 2 of CGEMS, rs1607237 was strongly associated with a decrease in breast cancer risk (OR=0.92, 95% CI 0.88--0.98, *P*=0.0050; [Table 2](#tbl2){ref-type="table"}).

This finding provided the rationale for further evaluation of this SNP in 23 BCAC studies involving women of European ancestry (28 766 cases, 28 319 controls), and two BCAC studies of Asian women (2183 cases, 1469 controls; [Table 1](#tbl1){ref-type="table"}). Rs1607237 was not significantly associated with breast cancer risk in the 23 BCAC studies of women of European ancestry (OR=0.98, 95% CI 0.96--1.01, *P*=0.139) or in the two Asian BCAC studies (OR=1.05, 95% CI 0.94--1.16, *P*=0.39; [Table 2](#tbl2){ref-type="table"}). However, when combining all genotype data from the three stages of this study (MCBCS, CGEMS and BCAC; [Supplementary Table 3](#sup1){ref-type="supplementary-material"}), rs1607237 was significantly associated with risk of breast cancer (OR=0.97, 95% CI 0.95--0.99, *P*=9.5 × 10^−3^). Similarly, a significant association was observed when considering only women of European ancestry in the combined analysis (OR=0.97, 95% CI 0.95--0.99, *P*=4.6 × 10^−3^; ([Table 2](#tbl2){ref-type="table"}). There was no evidence of heterogeneity by study site among the 25 Caucasian studies (*P*=0.14; [Supplementary Figure 2](#sup1){ref-type="supplementary-material"}).

To further understand the association with breast cancer, we restricted the analysis to women with invasive breast cancer. Rs1607237 was associated with a reduced risk of invasive breast cancer (OR=0.97, 95% CI 0.95--0.99, *P*=0.012; [Table 2](#tbl2){ref-type="table"}), whereas no association with risk of ductal carcinoma *in situ* was observed (OR=0.93, 95% CI 0.85--1.02, *P*=0.12). In addition, we explored differences in *PIK3CA* SNP associations in the combined data set by tumour subtype ([Supplementary Table 4](#sup1){ref-type="supplementary-material"}). The rs1607237 variant was not associated with any subtypes defined by ER, PR or HER2 status, although it is important to note the reduction in sample size when restricting to these tumour subtypes.

Discussion
==========

Here we report an association between inherited variation in the oncogene *PIK3CA* and risk of breast cancer in a large, three-stage analysis utilising nearly 75 000 subjects from 27 case--control study studies. We show that rs1607237 is significantly associated with a small decrease in breast cancer risk (OR=0.97, 95% CI 0.95--0.99, *P*=9.5 × 10^−3^) in all studies combined and when considering only women of European ancestry in the combined studies (OR=0.97, 95% CI 0.95--0.99, *P*=4.6 × 10^−3^). However, the association did not achieve significance in the large third stage involving only BCAC studies. Although the first two stages of our analysis suggest an association between *PIK3CA* and breast cancer risk, our inability to confirm this finding in the BCAC studies suggests that the result should be interpreted with caution.

We further explored the linkage disequilibrium patterns in the *PIK3CA* coding and promoter regions to better understand the relationship between rs1607237 and other variation in this region. Rs1607237 was not in strong linkage disequilibrium with two non-synonymous polymorphic variants in the coding region of *PIK3CA*, rs1051399 (*r*^2^=0.0060) and rs3729680 (*r*^2^=0.034), which had been genotyped in HapMap samples of European ancestry. However, an additional 18 non-synonymous variants were either not polymorphic or had not been genotyped in the HapMap samples, making inference about the relationship between rs1607237 and all variants of unknown significance in the *PIK3CA* coding region difficult. In addition, two *PIK3CA* promoter SNPs were in low LD with rs1607237 (rs9831234, *r*^2^=0.16; rs2865084, *r*^2^=0.038). However, it remains possible that *PIK3CA* promoter SNPs that were not captured in this study are related to breast cancer risk.

It is also important to note that the effect estimate for rs1607237 in the BCAC replication studies and in the overall BCAC, MCBCS and CGEMS studies is quite small (OR=0.97). This limits our statistical power to detect significant associations in these studies despite the large sample size, particularly in analyses utilising pathology information that is available for only a subset of subjects. Similarly, we had limited power to detect associations in the original MCBCS study with the three non-significant *PIK3CA* SNPs. Thus, it remains possible that evaluation of these variants in the larger BCAC cohort might detect associations with risk. While the effect of rs1607237 on risk is small, the association between inherited variation in this important oncogene and breast cancer risk does provide valuable biological insight into the development of this disease. Validation of rs1607237 in GWAS studies from other large collaborative groups and additional studies by BCAC with detailed pathology information are necessary to confirm this association. Functional evaluation of this variant is needed to fully understand the relationship between inherited *PIK3CA* variation and breast cancer risk.
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###### Studies contributing to evaluation of associations between rs1607237 and breast cancer risk

  **Study**[a](#t1-fn1){ref-type="fn"}   **Country**             **Cases *n* (%)**   **Controls *n* (%)**
  -------------------------------------- ----------------------- ------------------- ----------------------
  ABCFS                                  Australia               1199 (3.1)          438 (1.2)
  ABCS                                   The Netherlands         1465 (3.8)          548 (1.5)
  BBCC                                   Germany                 1060 (2.8)          994 (2.7)
  BBCS                                   UK                      1153 (3.0)          831 (2.3)
  BIGGS                                  Ireland                 1060 (2.8)          900 (2.5)
  CGEMS[b](#t1-fn2){ref-type="fn"}       USA                     5436 (14.2)         5280 (14.4)
  CNIO-BCS                               Spain                   752 (2.0)           823 (2.2)
  GC-HBOC                                Germany                 864 (2.3)           1224 (3.3)
  GENICA                                 Germany                 1013 (2.7)          1012 (2.8)
  GESBC                                  Germany                 563 (1.5)           564 (1.5)
  HABCS                                  Germany                 1046 (2.7)          998 (2.7)
  HMBCS                                  Belarus                 1760 (4.6)          1015 (2.8)
  KARBAC                                 Sweden                  812 (2.1)           863 (2.4)
  kConFab/AOCS                           Australia/New Zealand   566 (1.5)           899 (2.5)
  KBCP                                   Finland                 485 (1.3)           427 (1.2)
  MARIE                                  Germany                 2754 (7.2)          5302 (14.5)
  MBCSG                                  Italy                   739 (1.9)           1231 (3.4)
  MCBCS[c](#t1-fn3){ref-type="fn"}       USA                     1789 (4.7)          1554 (4.2)
  MCCS                                   Australia               679 (1.8)           751 (2.1)
  NC-BCFR                                USA                     388 (1.0)           154 (0.4)
  OBCS                                   Finland                 544 (1.4)           509 (1.4)
  OFBCR                                  Canada                  1170 (3.1)          329 (0.9)
  SBCS                                   UK                      1217 (3.2)          1201 (3.3)
  SEARCH                                 UK                      6520 (17.1)         6779 (18.5)
  SEBCS[d](#t1-fn4){ref-type="fn"}       Korea                   1732 (4.5)          1178 (3.2)
  TBCS[d](#t1-fn4){ref-type="fn"}        Thailand                451 (1.2)           291 (0.8)
  UCIBCS                                 USA                     957 (2.5)           527 (1.4)
  Total                                                          38 174 (100)        36 622 (100)

See [Supplementary Table 1](#sup1){ref-type="supplementary-material"} for definition of study acronyms.

Stage 2: Cancer Genetic Markers of Susceptibility study.

Includes Stage 1: Mayo Clinic Breast Cancer Study.

Asian case--control studies.

###### Associations between rs1607237 and breast cancer in MCBCS, CGEMS and BCAC

                                                                     **2-d.f. model**    
  ------------------- -------- -------- ------------------- -------- ------------------- -------------------
  Stage 1: MCBCS      798      843      0.85 (0.73--0.98)   0.023    0.75 (0.60--0.93)   0.76 (0.57--1.01)
  Stage 2: CGEMS      5436     5280     0.92 (0.88--0.98)   0.0050   1.00 (0.92--1.09)   0.82 (0.73--0.92)
  Stage 3: BCAC       28 766   28 319   0.98 (0.96--1.01)   0.139    0.96 (0.93--1.00)   0.97 (0.92--1.02)
  Combined analysis   35 991   35 153   0.97 (0.95--0.99)   0.0046   0.97 (0.93--1.00)   0.94 (0.90--0.98)
  Invasive            33 660   34 988   0.97 (0.95--0.99)   0.012    0.97 (0.94--1.00)   0.95 (0.90--0.99)
  DCIS                1159     16 889   0.93 (0.85--1.02)   0.12     0.98 (0.85--1.12)   0.84 (0.70--1.02)

Abbreviations: BCAC=Breast Cancer Association Consortium; CGEMS=Cancer Genetic Markers of Susceptibility; CI=confidence interval; DCIS=ductal carcinoma *in situ*; MCBCS=Mayo Clinic breast cancer case--control study; OR=odds ratio.

[^1]: See [Appendix](#app1){ref-type="app"}.
